Antagonism of haloperidol-induced swim impairment in l-dopa and caffeine treated mice: A pre-clinical model to study Parkinson's disease

Journal of Neuroscience Methods

Volumn 178, Issue 2, 2009, Pages 284-290

  Luthra, Pratibha Mehta ^a   Barodia, Sandeep Kumar ^a   Raghubir, Ram ^b  

^a UNIVERSITY OF DELHI   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Extra pyramidal; Haloperidol; Latency; Parkinson's disease; Rigidity; Swim test

Indexed keywords

CAFFEINE; CARBIDOPA; DOPAMINE; GLUTATHIONE; HALOPERIDOL; LEVODOPA; SUPEROXIDE DISMUTASE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SWIMMING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CAFFEINE; CATALEPSY; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HALOPERIDOL; LEVODOPA; MALE; MICE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; POSTURE; SUPEROXIDE DISMUTASE; SWIMMING;

EID: 61349098481     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2008.12.019     Document Type: Article

References (39)

1. Alleva E., Seta D.D., Cirulli F., and Aloe L. Haloperidol treatment decreases nerve growth factor levels in the hypothalamus of adult mice. Prog Neuropsychopharmacol Biol Psychiatry 20 (1996) 483-489
2. 2a receptor antagonist. J Neurosci 20 (2000) 5848-5852
3. Baldessarini R.J. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the task force on late neurological effects of antipsychotic drugs. Am J Psychiatry 137 (1980) 1163-1172
4. Bishnoi M., Chopra K., and Kulkarni S.K. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 552 (2006) 55-66
5. Carvey P.M., Ptak L.R., Lin D., Lo E.S., Buhrfiend C.M., Drucker G.E., et al. Alterations in striatal neurotrophic activity induced by dopaminergic drugs. Pharmacol Biochem Behav (1993) 195-204
6. Chang E.B. Rigidity and aging: do we become more rigid in our ideas as we age?. Perspectives 17 (1993) 12-14
7. Costall B., and Naylor R.J. Mesolimbic involvement with behavioural effects indicating antipsychotic activity. Eur J Pharmacol 27 (1974) 46-58
8. 2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 573-590
9. Crocker S.J., Smith P.D., Jackson-Lewis V., Lamba W.R., Hayley S.P., Grimm E., et al. Inhibition of Calpains prevents neuronal and behavioral deficits in an MPTP Mouse Model of Parkinson's disease. J Neurosci 23 (2003) 4081-4091
10. Dall'Igna O.P., Souza G.O., and Lara D.R. Caffeine as a neuroprotective adenosine receptor antagonist. Ann Pharmacother 38 (2004) 717-718
11. Donnan G.A., Willis G.L., Kaczmarczyk S.J., and Rowe P. Motor function in the 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine treated mouse. J Neurol Sci 77 (1987) 185-191
12. Ferré S., Marschitz M.H., Andén M.G., Casas M., Ungerstedt U., and Andén N.E. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol 192 (1991) 31-37
13. Fisone G., Håkansson K., Borgkvist A., and Santini E. Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms. Physiol Behav 92 (2007) 8-14
14. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51 (1999) 83-133
15. Glazer W.M. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61 (2000) 16-21
16. Glod B.K., Stanczac K.I., Wozniac A., and Pakszys W. Determination of catecholamines and the total antioxidant potential of blood plasma by use of an improved RPHPLC-ED assay. Acta Chromatogr 14 (2004) 142-148
17. 2 receptor agonist and antagonist on brain activity in the rat assessed by functional magnetic resonance imaging. Brain Res 813 (1998) 367-373
18. Haobam R., Sindhu K.M., Chandra G., and Mohanakumar K.P. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res 163 (2005) 159-167
19. Hattori K., Uchino S., Isosaka T., Maekawa M., Iyo M., Sato T., et al. Fyn is required for haloperidol-induced catalepsy in mice. J Biol Chem 281 (2006) 7129-7135
20. Jackson M.E., Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 101 (2004) 8467-8472
21. Jaskiw G.E., and Bongiovanni R. Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat. Psychopharmacology (Berl) 172 (2004) 100-107
22. Kanda T., and Jenner P. Actions of adenosine antagonists in primate model of Parkinson's disease. Adenosine Receptors Parkinson's Dis (2000) 211-227
23. Kobayashi T., Araki T., Itoyama Y., Takeshita M., Ohta T., and Oshima Y. Effects of l-dopa and bromocriptine on haloperidol-induced motor deficits in mice. Life Sci. 61 (1997) 2529-2538
24. 2a receptor blocking agents induces caffeine-like locomotor stimulation in mice. Eur Neuropsychopharmacol 16 (2006) 129-136
25. Muralikrishnan D., and Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12 (1998) 905
26. Powell K.R., Iuvone P.M., and Holtzman S.G. The role of dopamine in the locomotor stimulant effects and tolerance to these effects of caffeine. Pharmacol Biochem Behav 69 (2001) 59-70
27. 2A receptor antagonists as a new agent for the treatment of Parkinson's disease. Trends Pharmacol Sci 18 (1997) 338-344
28. Sanberg P.R., Ossenkopp K.P., and Kavaliers M. Motor activity and movement disorders: research issues and applications. contemporary neuroscience (1996), Humana Press, Totowa, New Jersey 365 pp
29. Schmidt C.J., Black C.K., and Taylor V.L. l-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine to rats. Eur J Pharmacol 203 (1991) 41-49
30. Schmidt W.J., and Kretschmer B.D. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci Biobehav Rev 21 (1997) 381-392
31. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30 (2000) 171-182
32. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3 (1998) 123-134
33. Stoltz S., Humm J.L., and Schallert T. Cortical injury impairs contralateral forelimb immobility during swimming: a simple test for loss of inhibitory motor control. Behav Brain Res 106 (1999) 127-132
34. Wadenberg M.L., Soliman A., VanderSpek S.C., and Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001) 633-641
35. Wang S., Hu L.F., Yang Y., Ding J.H., and Hu G. Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?. Neuropharmacology 48 (2005) 984-992
36. Weihmuller F.B., Hadjiconstantinou M., and Bruno J.P. Acute stress or neuroleptics elicit sensorimotor deficits in MPTP treated mice. Neurosci Lett 85 (1988) 137-142
37. Weihmuller F.B., Hadjiconstantinou M., and Bruno J.P. Dissociation between biochemical and behavioral recovery in MPTP-treated mice. Pharmacol Biochem Behav 34 (1989) 113-117
38. Whitehead J., Rose S., and Jenner P. Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats. Eur J Neurosci 14 (2001) 851-860
39. Zhu Z., Bartol M., Shen K., and Johnson S.W. Excitatory effects of dopamine on subthalamic nucleus neurons: in vitro study of rats pretreated with 6-hydroxydopamine and levodopa. Brain Res 945 (2002) 31-40